Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment

Lehmann, Helmar C.; Burke, David; Kuwabara, Satoshi

doi:10.1136/jnnp-2019-320314

Cited by 183 publications

(152 citation statements)

References 70 publications

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Long‐term subcutaneous immunoglobulin (LT‐SCIg) is a safe, effective, and tolerable alternative therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) . The lower profile of side effects when compared with intravenous immunoglobulin (IVIg) and its comparable clinical efficacy, together with lower direct (drugs for premedication, health‐care professional time) and indirect costs (eg, loss of working time for the patient/caregiver, transport), make this treatment widely accepted and well tolerated, even for long‐term treatment.…”

Section: Introductionmentioning

confidence: 99%

Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin

et al. 2019

View full text Add to dashboard Cite

Introduction Despite the well‐described clinical efficacy of long‐term subcutaneous immunoglobulin (LT‐SCIg) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients, the neurophysiological effects of SCIg have been followed only for a short time and were not correlated with clinical parameters. Methods Fourteen CIDP patients were evaluated at baseline and after LT‐SCIg administration for 24 to 48 months. Nerve conduction studies were performed and clinical features were assessed for: (a) overall strength, by Medical Research Council sum score; (b) sensory function, by Inflammatory Neuropathy Cause And Treatment score; (c) disability, by Rasch‐built overall disability scale; (d) quality of life (QoL), by the EuroQol Visual Analog Scale. Results LT‐SCIg treatment improved clinical and neurophysiological features, preserving strength and improving sensory deficits, disability, and QoL. Clinical scores correlated with the amplitude of distal motor action (dCMAP) and sensory nerve action (SNAP) potentials. Discussion LT‐SCIg treatment demonstrates efficacy in maintaining and continuing clinical improvement at 24 to 48 months after start of treatment. dCMAP and SNAP amplitudes represent useful prognostic factors for functional outcome.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin

et al. 2019

View full text Add to dashboard Cite

show abstract

“…В ряде случаев при наличии настораживающих симптомов требуется исключение боррелиоза, системных заболеваний и наследственных нейропатий. В свою очередь, ХВДП может быть ассоциирована с лимфомой, гепатитом С и ВИЧ-инфекцией [1,2,7,13].…”

Section: классификация и краткое описание форм хронической воспалителunclassified

“…тем не менее определение данных антител еще не вошло в рутинную клиническую практику, необходимо проведение дальнейших исследований [7,10,28,29].…”

Section: участие авторовunclassified

See 1 more Smart Citation

Clinical heterogeneity of chronic inflammatory demyelinating polyneuropathy: diagnostic challenges

2020

View full text Add to dashboard Cite

Сhronic inflammatory demyelinating polyneuropathy (CIDP) is the most prevalent acquired dysimmune neuropathy with clinical picture of symmetric motor and sensory disturbances. Since the first description of CIDP, many atypical variants have been described, which may reach up to 50% of cases. Diagnosis of atypical CIDP may be challenging due to different clinical presentation and treatment response. Current researches improve our knowledge about dysimmune neuropathies and highlight the importance of its classification. Nowadays CIDP is considered as a spectrum of disorders rather than a separate disease entity. Up to date, more than 15 diagnostic criteria have been proposed reflecting the complexity of СIDP diagnosis. Many polyneuropathies may mimic CIDP, therefore CIDP is frequently a diagnosis of exclusion. The key diagnostic instrument is electroneuromyography; however, the issues related to results misinterpretation and some technical aspects are the most important in CIDP misdiagnosis. Supportive instrumental and laboratory methods have variable sensitivity and specificity, making challenging CIDP diagnosis, especially its atypical forms. The importance of an early and accurate diagnosis of CIDP is supported by an effective pathogenic treatment, which affects the patient's prognosis and level of disability.

show abstract

“…Die chronisch inflammatorische demyelinisierende Polyneuropathie (CIDP) stellt als Autoimmunerkrankung eine behandelbare Polyneuropathie dar [1][2][3]. Therapien der ersten Wahl dieser schwerwiegenden Erkrankung des peripheren Nervensystems sind Steroide, intravenöse Immunglobuline (IVIG) und Plasmaaustausch.…”

Section: Introductionunclassified

Therapien bei der chronisch inflammatorischen demyelinisierenden Polyneuropathie

Gingele¹,

Seeliger²,

Skripuletz³

2020

Nervenheilkunde

View full text Add to dashboard Cite

ZUSAMMENFASSUNGDie chronisch inflammatorische demyelinisierende Polyneuropathie (CIDP) ist eine behandelbare Erkrankung des peripheren Nervensystems. Ein schneller Therapiebeginn kann bei vielen Patienten zu einer Erkrankungsstabilisierung führen und somit körperliche Behinderungen lindern oder verbessern. Steroide, intravenöse Immunglobuline und Plasmaaustausch können initial eingesetzt werden. Seit 2018 steht eine Behandlung mit subkutanen Immunglobulinen zur Verfügung. Patienten, die sich unter der Behandlung mit intravenösen Immunglobulinen stabilisiert haben, können auf diese neue Therapieform umgestellt werden. Subkutane Immunglobuline bieten viele Vorteile, wie beispielsweise größere Flexibilität im Alltag durch die Möglichkeit der Heimbehandlung, und sie eignen sich deshalb besonders gut für die Langzeitbehandlung von CIDP-Patienten.

show abstract

Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment

Cited by 183 publications

References 70 publications

Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin

Clinical‐neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin

Clinical heterogeneity of chronic inflammatory demyelinating polyneuropathy: diagnostic challenges

Therapien bei der chronisch inflammatorischen demyelinisierenden Polyneuropathie

Contact Info

Product

Resources

About